AI Article Synopsis
- Encapsulating peritoneal sclerosis (EPS) is a rare but serious complication observed in pediatric patients undergoing chronic peritoneal dialysis (CPD), with a reported incidence of 1.9% in a study of 104 patients.
- Clinical signs of EPS appeared shortly after the removal of dialysis catheters, often following episodes of peritonitis, leading to a shift to hemodialysis.
- Individualized management approaches are essential, with recommendations for radiological evaluation in CPD patients who experience ultrafiltration failure.
Article Abstract
Encapsulating peritoneal sclerosis (EPS) is a serious complication of chronic peritoneal dialysis (CPD). In contrast to the adult population, there are few studies regarding EPS in paediatric CPD patients, and the majority of reported patients are from Japan. The aim of the present report is to define the incidence of EPS in our paediatric CPD patients and to describe the clinical and laboratory characteristics. A total of 104 paediatric patients were followed from November 1989 to November 2003 and two were diagnosed as EPS (1.9%). The dialysis periods of these patients were 45 and 53 months with 6 and 8 peritonitis episodes, respectively. Clinical signs of EPS developed 7 and 14 days after the removal of the dialysis catheter, and CPD was replaced by haemodialysis because of persistent peritonitis. One patient was well after surgical management but died 6 months later. The second patient who was treated with prednisolone remained well at 16 months. In conclusion, EPS is a rare but important complication of CPD. We recommend that all patients on CPD who develop ultrafiltration failure be evaluated radiologically for the occurrence of EPS. Management should be tailored to the individual patient.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1440-1797.2005.00416.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Unexpected finding of encapsulating peritoneal sclerosis: mind the cocoon.
BMJ Case Rep
January 2025
Nephrology and Transplantation, Erasmus MC, Rotterdam, The Netherlands
Here, we present a fatal case of a man in his 40s with encapsulating peritoneal sclerosis (EPS). In retrospect, a spot diagnosis on the abdominal CT scan. The patient presented with progressive abdominal complaints of pain and vomiting over the last 2 months.
View Article and Find Full Text PDFTrends in Colorectal Cancer Peritoneal Metastases Research: A Comprehensive Bibliometric Analysis.
J Gastrointest Cancer
January 2025
The First Laboratory of Cancer Institute, The First Hospital of China Medical University, Shenyang, 110001, China.
Background: Colorectal cancer (CRC) stands as the third most prevalent malignancy globally and is recognized as the second leading cause of cancer-related mortality. Notably, nearly 50% of individuals diagnosed with CRC ultimately develop metastatic disease, with the peritoneum emerging as the second most frequent site for metastatic spread. Recent advancements in therapeutic frameworks have enhanced both survival rates and quality of life metrics for patients afflicted with colorectal cancer peritoneal metastases (CRCPM).
View Article and Find Full Text PDFM3-DPPE Liposomal Nanoparticles Encapsulating CLEC12A Enhance CD206-Mediated Endocytosis and Efficacy in the Collagen-Induced Arthritis Model.
ACS Appl Bio Mater
January 2025
Department of Joint Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200120, China.
Objective: This study aimed to investigate the efficacy of M3-DPPE liposomal nanoparticles encapsulated with mRNA encoding cytokines (M3-mRNAs) in targeting macrophages for the treatment of inflammation-induced joint injury.
Methods: , M3-mRNAs were administered to peritoneal exudate macrophages (PEMs), and the uptake was assessed using flow cytometry. The mechanism of uptake was investigated by blocking the CLEC12A pathway with M3-SiCLEC12A and observing CD206-mediated endocytosis.
Encapsulating Peritoneal Sclerosis: The Consequence of Recurrent Spontaneous Bacterial Peritonitis.
Dig Dis Sci
January 2025
Department of Gastroenterology, Istanbul Faculty of Medicine, Istanbul University, Topkapi Mahallesi Millet Caddesi, Istanbul Tip Fakültesi, 34093, Istanbul, Turkey.
Mechanisms underlying the involvement of peritoneal macrophages in the pathogenesis and novel therapeutic strategies for dialysis-induced peritoneal fibrosis.
Front Immunol
January 2025
Department of Nephrology, Second Hospital of Jilin University, Changchun, China.
Long-term exposure of the peritoneum to peritoneal dialysate results in pathophysiological changes in the anatomical organization of the peritoneum and progressive development of peritoneal fibrosis. This leads to a decline in peritoneal function and ultrafiltration failure, ultimately necessitating the discontinuation of peritoneal dialysis, severely limiting the potential for long-term maintenance. Additionally, encapsulating peritoneal sclerosis, a serious consequence of peritoneal fibrosis, resulting in patients discontinuing PD and significant mortality.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!